TELA Bio, Inc. (TELA), a company specializing in soft tissue preservation and restoration, has reported a robust financial performance in its Third Quarter 2024 Earnings Conference Call. The company's revenues reached $19 million, marking a significant 26% increase compared to the same period last year. This growth is attributed to a surge in unit sales for its OviTex and OviTex PRS products and a notable expansion in the European market.
Key Takeaways
- TELA Bio's Q3 revenue increased by 26% year-over-year to $19 million.
- Unit sales for OviTex and OviTex PRS grew by 39% and 44%, respectively.
- European revenues saw a substantial rise of 67%.
- The company successfully closed a public offering, adding $43 million to its cash reserves.
- Operational cost savings are expected to reduce annual expenses by $5 million to $10 million.
- Full-year 2024 revenue guidance remains at $74.5 million to $76.5 million, a 28% to 31% growth from 2023.
- Management is confident in sustaining growth and establishing OviTex as a leading technology.
Company Outlook
- TELA Bio reiterated its full-year 2024 revenue guidance, reflecting a strong growth trajectory.
- The company is well-positioned for future growth and potential profitability with its increased cash reserves.
- Strategic initiatives, such as improved sales training, are enhancing commercial effectiveness.
Bearish Highlights
- A projected operational expense savings of $5 million to $10 million is primarily due to headcount reductions.
- Revenue recovery from Q2's cyberattack-related disruptions was not evident in Q3.
Bullish Highlights
- TELA Bio achieved its first $1 million month in Europe, indicating strong market share gains.
- The international market is performing well, and there is a shift toward natural repair methods, which TELA Bio's products cater to.
- October's record-high performance suggests a strong start to Q4 and confidence in meeting guidance.
Misses
- Despite returning to pre-disruption procedure rates, there was no significant backlog from the cyberattack in Q2, suggesting a missed opportunity for accelerated growth.
Q&A Highlights
- Executives discussed the strong start to Q4, with October marking a high point in performance.
- Roberto Cuca noted potential pressure on average selling prices due to increased volume of the OviTex IHR product.
- Tony Koblish highlighted the importance of continuous sales training to maintain a competitive edge.
In summary, TELA Bio is experiencing robust growth, particularly in Europe, and is taking strategic steps to maintain this momentum. The company's focus on data-driven sales and improved training for its sales force is paying dividends, as evidenced by the impressive sales figures of its OviTex products. While the company is cautious about the impact of increased volume on average selling prices, it remains confident in its ability to balance the market dynamics with its selling strategies. With a strong outlook for the remainder of the year and operational cost savings on the horizon, TELA Bio appears well-positioned for continued success in the soft tissue preservation and restoration market.
InvestingPro Insights
TELA Bio's strong financial performance in Q3 2024 is reflected in the latest InvestingPro data, which shows a robust revenue growth of 29.34% over the last twelve months. This aligns well with the company's reported 26% year-over-year increase in Q3 revenue. The company's gross profit margin stands at an impressive 68.86%, underscoring its ability to maintain profitability on its product sales despite potential pressures on average selling prices.
However, investors should note that TELA is currently not profitable, with an operating income margin of -66.45% over the last twelve months. This is consistent with the company's focus on growth and market expansion, particularly in Europe, where they achieved their first $1 million month.
InvestingPro Tips highlight that TELA has been "quickly burning through cash," which explains the recent public offering that added $43 million to its cash reserves. This move strengthens the company's financial position, as another InvestingPro Tip notes that "liquid assets exceed short term obligations," providing a buffer for continued growth initiatives.
The stock has shown strong performance recently, with a 29.2% return over the last month, indicating positive investor sentiment following the Q3 results. However, the longer-term picture shows volatility, with the stock taking "a big hit over the last six months," according to InvestingPro Tips.
For investors seeking a more comprehensive analysis, InvestingPro offers 5 additional tips that could provide further insights into TELA Bio's financial health and market position.
Full transcript - Tela Bio Inc (NASDAQ:TELA) Q3 2024:
Operator: Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the prepared remarks. As a reminder, this conference call is being recorded. I would now like to turn the conference over to Louisa Smith from the Gilmartin Group. Please go ahead.
Louisa Smith: Thank you, Leonardo, and good afternoon, everyone. Earlier today, TELA Bio released financial results for the third quarter of 2024. A copy of the press release is available on the company's website. Joining me on today's call are Tony Koblish, President and Chief Executive Officer; and Roberto Cuca, Chief Operating Officer and Chief Financial Officer. Before we begin, I'd like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's annual report on Form 10-K and quarterly reports on Forms 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development and pipeline opportunities, product potential, changes in surgical procedure volumes due to various factors and conditions identified in our filings, changes in the regulatory environment and in our sales and marketing strategies, our capital resources, and our operating performance. I'd now like to turn the call over to Tony.
Tony Koblish: Thanks, Louisa, and good afternoon, everyone. Thank you for joining TELA Bio's third quarter 2024 earnings call. Roberto and I will provide our respective updates on the quarter and review our financial results before we open the call up for your questions. I am pleased to report that we delivered a very strong third quarter that marked a return to growth rates across the portfolio more consistent with what we've delivered historically. Recall, last quarter, we had to work through the impact of cybersecurity events that affected some of our hospital customers. That effect appears confined to that period as evidenced by revenue for Q3 of $19 million, a 26% year-over-year increase. Demand for our portfolio of products was high with unit sales for OviTex and OviTex PRS growing 39% and 44% respectively, while our European business grew 67% from the prior year period. Global average daily sales exceeded $300,000 per day and there are now more than 700 hospitals worldwide using our products across a steadily growing GPO contract base. Additionally, we recently announced the closing of a public offering that added $43 million of cash to the balance sheet. As a result, we believe that we are amply funded to continue driving strong revenue growth and reach profitability. With that overview, let me provide some additional details, starting with the dynamic international growth we generated this quarter. Europe's performance has been particularly strong with significant market share gains in U.K., Germany, the Netherlands, Austria and Switzerland, along with promising early results in Spain and Portugal. In Q3, we achieved our first $1 million month in Europe. With OviTex firmly established as a market leader in the U.K. and the Netherlands, supported by encouraging clinical data presented in journals and at congresses, we are effectively adjusting to Europe's widely practiced and U.K. mandated model of patient consent or shared decision-making to guide us in developing tools that better support surgeons worldwide in this essential practice. These tools empower informed choices aligning with our commitment to patient centered care globally. The shift from polypropylene and synthetic mesh towards a more natural repair product like OviTex is steadily gaining recognition for its safety profile and clinical benefits. We have implemented multiple strategic initiatives to leverage recent shifts in the market to position OviTex as the preferred choice for surgeons and their patients when deliberately opting out of plastic. In hernia and abdominal wall reconstruction, we sold nearly 5,000 OviTex units this quarter with 60% usage in minimally invasive procedures, reflecting strong adoption of OviTex LPR and IHR products. Our plastic and reconstruction portfolio also saw significant growth fueled by OviTex, PRS, LTR, topping $6.3 million in Q3. I am also very pleased to report, we are doing a very effective job gaining mind share among surgeons. Q3 was a standout period for TELA Bio at key society meetings, exposing us to thousands of potential surgeon customers. At the American Hernia Society meeting in Chicago, we generated significant awareness around TELA's brand and its products, including by hosting a highly attended lunch symposium, featuring global thought leader Professor, Marja Boermeester from Amsterdam, speaking about her experience with OviTex in complex hernia repairs. We were also able to host a unique evening reception with AHS and a couple of hundred surgeons where Professor Boermeester captivated everyone again with her talent this time as DJ eMBee. We also continued to drive exposure in the PRS arena and sponsored the welcome reception at Plastic Surgery The Meeting, where we were able to reinforce our commitment to innovation and partnership in plastic and reconstructive surgery to the nearly 2,000 surgeons in attendance at the conference. Our meeting presence also included expanded partnership with Intuitive Surgical (NASDAQ:ISRG) at their 360 meeting for hospital and health system leadership and a symposium at the American Foregut Society meeting, where renowned former Society President, Reg Bell shared his insights on OviTex. Commercially, we are set to benefit from a growth strategy that is based on data-driven selling across the whole portfolio. We appointed Greg Firestone, the Chief Commercial Officer in May and he wasted no time making important changes to our commercial strategy that have already resulted in a more productive sales organization. Most notably, the deep PRS training and skill assessment that began in the late fall of 2023 and extended through this year has involved our sales force's balanced selling across both PRS and hernia product lines. These improvements across our training and development program have also enabled us to streamline our commercial organization with a focus on more productive quota-carrying sales representatives and less on other auxiliary functions that have historically supported our sales organization in PRS and other highly specialized applications. We are already seeing those benefits and believe the strength of performance in the third quarter is indicative of early success and sustainable growth moving forward as we continue to evaluate and evolve our teams to support a more efficient commercial organization. From a financial perspective, we have also made notable progress. We implemented changes in the third quarter that will annualize to approximately $5 million to $10 million in OpEx reduction with some of the savings expected in the fourth quarter and the full impact manifesting in 2025. These changes in conjunction with the recent public offering that added $43 million in cash to our balance sheet should allow us to reach breakeven while maintaining a solid growth trajectory. I look forward to speaking less about our balance sheet and more about operational performance in the coming quarters. I'll now turn the call over to Roberto to review our financial results in more detail.
Roberto Cuca: Thanks, Tony. As Tony mentioned, revenue for the third quarter of 2024 grew 26% year-over-year or nearly $4 million to $19 million with revenue from OviTex growing 23% and OviTex PRS growing 31%. Gross margin was 68% for the third quarter compared to 69% in the prior year period. The decrease was primarily due to a higher charge for excess and obsolete inventory as a percentage of revenue. Sales and marketing expense was $16.5 million in the third quarter of 2024 compared to $14.5 million in the same period in 2023. The increase was primarily due to increased compensation costs, including increased severance costs and additional consulting and travel expenses. General and administrative expense was $3.7 million, effectively flat when compared to the same period in 2023. R&D expense was $2.1 million in the third quarter compared to $2.4 million in the prior year period. The decrease was primarily due to lower study and development costs, which offset higher compensation and benefits. Loss from operations was $9.4 million in the third quarter of 2024 compared to $10.2 million in the prior year period. Net loss was $10.4 million in the third quarter of 2024 compared to $11 million in the same period in 2023. As we've disclosed previously, we still expect operating loss and net loss to be less in 2024 than in 2023, even excluding the impact of the NIVIS divestiture. We expect operating expenses will be lower sequentially in the fourth quarter as cost-saving efforts expected to reduce 2025 OpEx by $5 million to $10 million from annualized first half of 2024 OpEx begin to kick in. We ended the third quarter with $17.3 million in cash and cash equivalents. After the end of the quarter, we conducted a public equity offering resulting in net proceeds of approximately $43 million. Turning to the outlook for 2024. With the strong return to growth in the third quarter, we remain on track to achieve our previously issued full year revenue guidance from $74.5 million to $76.5 million, reflecting growth of 28% to 31% over 2023 across that range. This estimate does not include the potential effects of IV fluid shortages resulting from recent natural disasters. We are carefully monitoring elective procedure volumes for evidence of disruption and to enable potential remedial actions but as of yet have been unable to detect a meaningful impact. I'll now hand the call back to Tony for closing remarks.
Tony Koblish: Thanks, Roberto. In closing Q3 has been an exceptional quarter for TELA Bio both financially and operationally, as we continue to accelerate our momentum in hernia and PRS while reinforcing our leadership in innovation and surgeon education. From achieving record-breaking average daily sales to crossing the milestone of our first $1 million month in Europe, we continue to drive growth across markets and deliver on our mission. I have never been more confident in our prospects to establish OviTex and OviTex PRS as the leading technology in soft tissue preservation and restoration. What is most exciting is that we are just getting started as most of the market remains up for the taking. Lastly, I want to speak directly to TELA Bio's employees both here in Malvern and in the field our commercial team. I'd like to thank you and acknowledge your dedication, tenacity, unity and resilience in overcoming the headwinds in prior quarter Q2 and delivering an exceptional Q3. We thank you very much. It was a great effort and we look forward to continuing the path for future success. So with that, I'll now ask Leonardo to open the line for questions. Please go ahead.
Operator: Thank you. We will now begin the question-and-answer session. [Operator Instructions] Your first question comes from the line of Caitlin Cronin of Canaccord. Please go ahead.
Caitlin Cronin: Hey, guys. Congrats on a great quarter.
Tony Koblish: Thanks, Caitlin.
Caitlin Cronin: Yes, just to start off, can you provide a little more color on the $5 million to $10 million in OpEx savings? Where are these coming from? And are these savings just for Q4 and 2025 or sustainable beyond that?
Roberto Cuca: So thanks for the question Caitlin. I'll start off and Tony can jump in. So the primary source of the savings are headcount reductions that we implemented in the first part of the third quarter. So we began more intensive training on PRS selling for our sales force about a year ago at the behest of our now Chief Commercial Officer, Greg Firestone. As our sales force became more adept at selling across the portfolio, so both hernia products and PRS products and relied less on clinical development specialists to assist them in the PRS sales in specific, we were able to redeploy some of those more expensive clinical development specialists and also reduce the total size of that force as well as some other supportive heads. So Greg talks about our sales and marketing organization being broken into doers and helpers, where doers are the people who carry the quotas and everyone else is a helper. So we were able to reduce our reliance on helpers while keeping the focus on quota-carrying sales reps. We believe that those reductions are such that we'll be able to carry them from the 2025 into 2026 as well. And as Greg continues to take a look at the sales organization there could be other places where we can become more efficient.
Caitlin Cronin: Great. And then just turning to revenue for the quarter. Did you recover procedures from the cyberattack challenges in Q2? And how much of the revs in Q3 were related to the clearing of that backlog?
Tony Koblish: Yes. I mean I think from our COVID experience Caitlin, we just never see a backlog load up and then flow through the system. In hernia, it just seems like the procedures fade and then come back to more normal levels. And I think that's what we saw here. There was really no that we could discern load up of patients that entered the system into Q3. I actually think that through the cyber hack problems at the one GPO, those patients might have actually been rerouted to other places perhaps where we don't have customers or we don't have a footprint. So I don't think all of those patients were reallocated but I think some were. And hernia just seems to be one of those quasi-elective procedures, where watchful waiting as part of the treatment algorithm anyway. So plus or minus a quarter or two for most procedures is probably very much doable in the cycle of treatment. So I don't think we saw much of a load up from Q2.
Roberto Cuca: Yes. And I'd add Caitlin, we don't think that Q3 was boosted by backlog from Q2 because in order for that to have happened. You would have had to see a higher rate of procedures at the affected hospitals in Q3 than you saw in Q1. And what we really saw was that the rate was returning to the pre-disruption level.
Caitlin Cronin: Got it. Makes sense. Thanks, guys.
Roberto Cuca: Thanks, Caitlin.
Operator: Your next question comes from the line of Frank Takkinen of Lake Street Capital Markets. Please go ahead.
Frank Takkinen: Great. Thanks for taking the question. Congrats on the quarter. Maybe I was going to start with talking a little bit about 2025. I'm sure there's a little reluctance to speak to too much detail about it but maybe initial thoughts as we enter the year into 2025, how we're thinking about growth. I think consensus right now is in the 25% range. Any reaction to that? And any thoughts around that growth profile?
Roberto Cuca: So we haven't provided guidance for 2025 yet. We typically do that on our fourth quarter earnings call. We are guiding to 26% to 31% growth for this year, 25% is a little below that. You do see that as the company matures, the growth rate can throttle back. Obviously, that's just below the lower end of the current range for this year, a year where we had the second quarter disruption. So I don't think it's out of line in any direction. But as we complete our own budgeting process internally and then get into the fourth quarter earnings call we'll provide an update on what our expectations are for next year.
Frank Takkinen: Got it. That's helpful. And then maybe swinging back to some of Tony's prepared remarks on the international front. It sounds like things are going really well there. What can you extrapolate from that market and apply to the US market, especially in light of some of the synthetic settlements that are occurring and maybe the trend away from synthetics?
Tony Koblish: Yes. Thanks for that. I think – I think it's an interesting thought experiment. If you look at the UK and the NHS, they've put together a program called get it right the first time. And there is this collaboration that the NHS is driving between surgeons and patients to have almost a consent process or a shared decision-making process on the mode of treatment. And certainly, mode of treatment for hernia repair is what type of mesh is the patient comfortable with and what kind of mesh is the surgeon comfortable with. And I think this shared decision-making model has been something we have used here in the US quite a bit. And I think we've actually published a little bit of data on that that shows that if you show all the different samples of product out that are available, whether it's permanent plastic or temporary plastic or biologic or our reinforced tissue matrix that well into the 90% of the time, the patient will have a conversation with the surgeon about our product. So it seems to be an effective way to get everybody educated on natural repair with the reinforced tissue matrix. And I think we're seeing a little bit of that taking effect in the UK, which is a country that is – the size of the UK. And so if we extrapolate that model becoming more popular and more used in the US with 350 million people, I think it shows that we are heading in the right -- we are in the right place for where this market is heading. I think it's unquestionably clear that there will come a day where permanent plastic is less implanted in the US than it is today. I think it's probably 80% of all implants that go in today believe it or not even with some of the litigation and settlements that have played out of size -- of considerable size. So that's going to change over time. I think it's just a natural force of innovation and evolution. And if a shared decision-making model similar that's coming out of the NHS in the UK gain some traction here, it's going to be great for us. But certainly, the shift towards natural repair is going to be great for us. We're sitting in a good spot over the next, I'd say, five years.
Frank Takkinen: Got it. Okay. That’s helpful. Thanks for taking the questions.
Tony Koblish: Thanks, Frank.
Operator: [Operator Instructions] your next question comes from the line of Michael Sarcone of Jefferies. Please go ahead.
Michael Sarcone: [Technical Difficulty] You're seeing so far through the fourth quarter to-date?
Roberto Cuca: Sorry, the first part of your question cut out through. Can you repeat it?
Michael Sarcone: Yes sure. I was just curious what kind of trends you're seeing so far in the fourth quarter. And should we expect that OviTex IHR is going to continue to grow pretty rapidly and we'll continue to see some of those mix shifts drive ASP pressure?
Roberto Cuca: Yes. So we talked about in our last call what the first month of the quarter looked like, because there was some concern about weather disruptions lagging over into the third quarter from the second quarter. We are seeing a similar progression in the fourth quarter, meaning that October is a record high first month of a quarter for us suggesting that we're on track to hit the fourth quarter numbers that we need to hit to get to our guidance. And then the second part of your question was...
Tony Koblish: IHR and price pressure. Yes. So, I think IHR is off to a good start. We're only about a quarter in that rollout. I think as the volume goes up, there there's going to be some puts and takes Michael, right? So IHR volume could bring ASP generally down. But our encouragement of balanced selling is going to mean that we want to go after all of the different hernias that are out there including ventrals and complex ab walls, which is where we got our start quite successfully. So it stands to reason that as our ventral and complex users get into IHR, IHR will grow. And as new users develop an interest and start using IHR, hopefully our ventral and complex products will grow. So there may be a little bit of a put and take on ASP depending on the ratio of the bigger pieces in the complex and the IHR product. So I think in general, the ASP will come down as the IHR volume goes up but there could be some offsets as well.
Michael Sarcone: Got it. Thanks Tony. That's helpful. And I guess you talked about the balanced selling and you gave some color around sales rep training and productivity. Do you think you can elaborate a little more? Are you basically through a lot of the initial training that you had planned? Or is this going to be kind of a continuous process to improve rep productivity over time?
Tony Koblish: Yes. I think our model, Michael, is perpetual training right? This market is so dynamic and it's changing so rapidly that we have to continue to stay on top of the training. So, we've hired a purpose-built training team that is going to focus on both first training, second training, field training, basically Zoom (NASDAQ:ZM) update calls. So, essentially perpetual training. This is something that we deeply believe in. It gives us a competitive advantage. We have a lot of innovation and clinical data to talk about that's positive. So we are really going to up the ante on our training going forward.
Michael Sarcone: Great. Thank you.
Tony Koblish: Thank you, Michael.
Operator: Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.